Table 1. Baseline Characteristics for Patients Who Had Taken Oral Semaglutide (N = 47).
| Clinical characteristics | |
|---|---|
| Age (years old) | 58.2 ± 13.5 |
| Gender (male/female) | 25/22 |
| Body weight (mean ± SD, kg) | 78.9 ± 17.7 |
| Body mass index (mean ± SD, kg/m2) | 30.5 ± 6.0 |
| Systolic blood pressure (mean ± SD, mm Hg) | 133.1 ± 14.1 |
| Diastolic blood pressure (mean ± SD, mm Hg) | 77.9 ± 10.6 |
| Comorbidities | |
| Dyslipidemia (n, %) | 43, 91.5% |
| Hypertension (n, %) | 30, 63.8% |
| Hyperuricemia (n, %) | 12, 25.5% |
| Treatments for type 2 diabetes | |
| Dipeptidyl peptidase-4 inhibitors (n, %) | 30, 63.8% |
| Metformin (n, %) | 35, 74.5% |
| Sodium-glucose cotransporter 2 inhibitors (n, %) | 39, 83.0% |
| Sulfonylurea (n, %) | 8, 17.0% |
| α-glucosidase inhibitors (n, %) | 7, 15.0% |
| Pioglitazone (n, %) | 17, 36.2% |
| Insulin (n, %) | 3, 6.4% |
| Glucagon-like peptide 1 analogues (n, %) | 11, 23.4% |
| Treatments for hypertension | |
| Angiotensin receptor blockers (n, %) | 28, 59.6% |
| Calcium antagonists (n, %) | 15, 31.9% |
| Diuretics (n, %) | 2, 4.3% |
| α, β-blockers (n, %) | 4, 8.5% |
| Treatments for dyslipidemia | |
| Statins (n, %) | 31, 66.0% |
| Ezetimibe (n) | 6, 12.8% |
| Eicosapentaenoic acid (n, %) | 6, 12.8% |
| Pemafibrate (n, %) | 5, 10.6% |
| Fenofibrate (n, %) | 1, 2.1% |
| Treatments for hyperuricemia | |
| Febuxostat (n, %) | 3, 8.9% |
| Topiroxostat (n, %) | 1, 3.3% |
| Allopurinol (n, %) | 2, 4.9% |
| Dotinurad (n, %) | 1, 3.3% |
SD: standard deviation.